Structure Therapeutics: The Amylin Data Changes The Math

Structure Therapeutics (GPCR) outlook: aleniglipron obesity data de-risks lead asset, amylin adds upside, cash strong—see ...
BioSpace

Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop

Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, ...

Structure Therapeutics falls after trial data for lead obesity drugs

Structure Therapeutics (GPCR) stock slides in reaction to trial data for the company's lead obesity candidates, ACCG-2671 and ...

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase ...

Structure Therapeutics advances weight-loss pills with new clinical data

Structure Therapeutics Inc. GPCR on Tuesday announced encouraging clinical trial findings for two of its main oral drug ...